Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study
- DOI
- 10.1007/s00262-026-04517-6
- Published
- 2026-08-10
- Container
- Cancer Immunology, Immunotherapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s00262-026-04517-6,
title = {Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study},
author = {Weixuan Pan and Mingchang Pang and Hu Li and Pengfei Hui and Zijian Leng and Guanhua Yu and Xinyuan Chen and Zhenyu Zhu and Haitao Zhao and Yongchang Zheng},
year = {2026},
journal = {Cancer Immunology, Immunotherapy},
doi = {10.1007/s00262-026-04517-6},
url = {https://doi.org/10.1007/s00262-026-04517-6}
}RIS
TY - JOUR TI - Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study AU - Weixuan Pan AU - Mingchang Pang AU - Hu Li AU - Pengfei Hui AU - Zijian Leng AU - Guanhua Yu AU - Xinyuan Chen AU - Zhenyu Zhu AU - Haitao Zhao AU - Yongchang Zheng PY - 2026 JO - Cancer Immunology, Immunotherapy DO - 10.1007/s00262-026-04517-6 UR - https://doi.org/10.1007/s00262-026-04517-6 ER -
APA
Pan, W., Pang, M., Li, H., Hui, P., Leng, Z., Yu, G., Chen, X., Zhu, Z., Zhao, H., & Zheng, Y. (2026). Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04517-6
Source records
- crossref · retrieved 2026-11-10T19:13:35.447Z